Literature DB >> 7812631

Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.

J J Maguire1, R E Kuc, G O'Reilly, A P Davenport.   

Abstract

1. We have identified the endothelin receptors present in the media of human main stem renal artery and vein and characterized the subtypes mediating vasoconstriction in these blood vessels in vitro. 2. Messenger RNA encoding both ETA and ETB receptors was identified in the smooth muscle layer of human renal artery and vein by reverse transcriptase-polymerase chain reaction assay. In cryostat-cut cross-sections of both vessels autoradiographical visualisation suggested a majority of ETA receptors. Intense binding was obtained to the non-selective ligand [125I]-ET-1 and the ETA-selective [125I]-PD151242 but only weak labelling of sites by the ETB-selective [125I]-BQ3020. 3. ET-1 potently constricted renal artery and vein preparations with EC50 values of 4.06 nM and 1.00 nM, respectively. Sarafotoxin 6b was approximately ten times less potent than ET-1 with EC50 values of 36.3 nM and 13.8 nM respectively. In the renal artery, ET-3 and sarafotoxin 6c showed little or no activity up to 300 nM. Responses to these peptides were more variable in the renal vein. Preparations from three individuals did not respond to ET-3 but in three further cases, although ET-3 was much less potent than ET-1, full dose-response curves were obtained. S6c elicited dose-related contractions in vein preparations from 5/6 individuals and although more potent than ET-1, the maximum response was 30-60% of that obtained to ET-1. 4. ET-1-induced vasoconstriction of renal artery and vein was antagonized by the ETA-selective, BQ123 (3-10 microM). The dose-response curves to ET-1 were displaced in a parallel rightward fashion with no attenuation of the maximum responses. pA2 values were estimated to be 6.8 +/- 0.1 and 6.8 +/- 0.4 for artery and vein respectively.5. These data suggest that mRNA encoding both ETA and ETB receptors is present in the media of human main stem renal artery and vein. However, autoradiographical studies indicate that the majority of ET receptors expressed are of the ETA subtype. The relative potencies of ET-1 and ET-3 as vasoconstrictors of renal blood vessels in vitro is consistent with this being an ETA-mediated response,and therefore whilst responses to S6c indicate that constrictor ETB receptors may be present in renal veins from some individuals these are likely to be of less importance in these blood vessels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7812631      PMCID: PMC1510060          DOI: 10.1111/j.1476-5381.1994.tb16172.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo.

Authors:  M Clozel; G A Gray; V Breu; B M Löffler; R Osterwalder
Journal:  Biochem Biophys Res Commun       Date:  1992-07-31       Impact factor: 3.575

Review 2.  Molecular characterization of endothelin receptors.

Authors:  T Sakurai; M Yanagisawa; T Masaki
Journal:  Trends Pharmacol Sci       Date:  1992-03       Impact factor: 14.819

3.  Increased endothelin level after cyclosporine therapy.

Authors:  G Deray; A Carayon; P Le Hoang
Journal:  Ann Intern Med       Date:  1991-05-01       Impact factor: 25.391

4.  Plasma endothelin levels in patients with uraemia.

Authors:  H Koyama; T Tabata; Y Nishzawa; T Inoue; H Morii; T Yamaji
Journal:  Lancet       Date:  1989-05-06       Impact factor: 79.321

5.  Endothelin-3 concentrations in human plasma: the increased concentrations in patients undergoing haemodialysis.

Authors:  N Suzuki; H Matsumoto; T Miyauchi; K Goto; T Masaki; M Tsuda; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1990-06-15       Impact factor: 3.575

6.  Plasma endothelin levels in patients with acute renal failure.

Authors:  K Tomita; K Ujiie; T Nakanishi; S Tomura; O Matsuda; K Ando; M Shichiri; Y Hirata; F Marumo
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

7.  Upregulation of renal endothelin receptors in rats with cyclosporine A-induced nephrotoxicity.

Authors:  P Nambi; M Pullen; L C Contino; D P Brooks
Journal:  Eur J Pharmacol       Date:  1990-10-02       Impact factor: 4.432

8.  Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity.

Authors:  A Fogo; S E Hellings; T Inagami; V Kon
Journal:  Kidney Int       Date:  1992-09       Impact factor: 10.612

9.  ETA receptor-mediated responses to endothelin-1 and big endothelin-1 in the rat kidney.

Authors:  D M Pollock; T J Opgenorth
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  Plasma levels of endothelin in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity.

Authors:  F Stockenhuber; M Gottsauner-Wolf; L Marosi; B Liebisch; R W Kurz; P Balcke
Journal:  Clin Sci (Lond)       Date:  1992-03       Impact factor: 6.124

View more
  17 in total

1.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

2.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

3.  The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects.

Authors:  C Weber; L Banken; H Birnboeck; S Nave; R Schulz
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

4.  Characterization of endothelin receptors in the human umbilical artery and vein.

Authors:  G Bogoni; A Rizzi; G Calo; C Campobasso; P D'Orleans-Juste; D Regoli
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

5.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  Endothelin receptors in human coronary artery and aorta.

Authors:  C R Bacon; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

7.  Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

8.  Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments.

Authors:  J J Maguire; R E Kuc; B A Rous; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

9.  Characterization of endothelin receptors in rat renal artery in vitro.

Authors:  K L Clark; L Pierre
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

10.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.